Consort. (A) Cohort 1: alternate therapy group. Of 2551 total patients diagnosed with DLBCL and treated at MSKCC, 186 patients had at least 3 lines of therapy and available outcome data at the third line. Of these, 12 were excluded because they were treated with indolent lymphoma-directed therapy (eg, rituximab) as a prior line, 23 were excluded for CNS-only disease, and 5 who ultimately received commercial CAR T therapy were duplicate patients included in the other cohort. The final inclusion population consisted of 146 patients. (B) Cohort 2: CAR T therapy group. Of 72 patients who were referred to MSKCC for commercial CAR T therapy beginning in February 2018, 3 were excluded because they were treated off-label as part of a research protocol. The final inclusion population consisted of 69 patients, of which 47 received axicabtagene ciloleucel and 22 tisagenlecleucel.